Dallas, Texas 03/18/2014 (FINANCIALSTRENDS) – Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) may have found its muse in its RX-5902, now named Supinoxin finally. With the first-stage results of Supinoxin announced last week, the clinical-stage therapy appears to meet requirements for treating nervous system disorders as well as cancer. More importantly, Supinoxin is found to hit the right chemicals to break down solid cancer tumors.
Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) has announced that the results, which are of the Phase One Study, begun in the eight month of last year is yet to achieve MTD or Maximum Tolerated Dose and is ongoing.
Currently, the cycles were completed thrice and there has been no trace of anti-drug issues.
Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) in its press release noted that, “Pharmacokinetic analysis has shown that SupinoxinTM displays dose-proportional exposure and an estimated oral bioavailability of 51%.”
Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN), in the context of the results thus far has proved to be drug which does trigger immediate anti-factors. Instead patients have indicated higher tolerance. The current results are aligned with the preliminary clinical studies as well.
Full Phase Data to define RNN future
However, Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN) awaits the full results of the Phase One study, which are likely to be available by the end of the year, when the study of this phase will end.
Though, current investors in RNN do hope the results of these initial studies and first-stage human trials relate to the final results, experts in this sector, do advice caution.
First, the drug is yet to achieve a critical MTD value. Once this is recognized the real-time viability of Supinoxin comes into picture. Besides, efficacy factors too need to be established, before Supinoxin becomes popular for treating solid tumors as well as disorders of the nervous system.
RNN currently holds a market capital of $59.80 million and trades at infra-day prices between $1.28 and $1.29 per share.